The trifunctional antibody (trAb) catumaxomab (anti-EpCAM x anti-CD3, removab) represents a new class of intact antibodies, which are able to re-direct T-lymphocytes to tumor cells and to induce ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

AbbVie partners with Ichnos Glenmark to develop ISB 2001, a trispecific antibody for multiple myeloma, in a $1.9B licensing ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

New spinal cord implants promise safer, long-term recovery options for SCI patients, boosting movement, sensation, and hope.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On ...

Rheumatoid arthritis and spondyloarthritis are long-lasting inflammatory diseases that gradually wear down joints. While ...

Explore the rise and market race of anti-IL23p19 therapies in Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC). Stay informed on the latest advancements and treatment options.

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD).